GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (CHIX:DIMp) » Definitions » Revenue

Sartorius Stedim Biotech (CHIX:DIMP) Revenue : €2,069 Mil (TTM As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Sartorius Stedim Biotech Revenue?

Sartorius Stedim Biotech's revenue for the three months ended in Sep. 2024 was €655 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was €2,069 Mil. Sartorius Stedim Biotech's Revenue per Share for the three months ended in Sep. 2024 was €6.68. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €21.80.

Warning Sign:

Sartorius Stedim Biotech SA revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Sartorius Stedim Biotech was -15.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 13.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 22.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 19.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Sartorius Stedim Biotech's highest 3-Year average Revenue per Share Growth Rate was 34.30% per year. The lowest was -8.80% per year. And the median was 13.10% per year.


Sartorius Stedim Biotech Revenue Historical Data

The historical data trend for Sartorius Stedim Biotech's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Revenue Chart

Sartorius Stedim Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,440.57 1,910.08 2,887.00 3,492.70 2,775.50

Sartorius Stedim Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 675.70 666.90 706.80 706.40 655.40

Competitive Comparison of Sartorius Stedim Biotech's Revenue

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech's Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Revenue distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Revenue falls into.



Sartorius Stedim Biotech Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,069 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius Stedim Biotech  (CHIX:DIMp) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Sartorius Stedim Biotech Revenue Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius Stedim Biotech Business Description

Address
Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.

Sartorius Stedim Biotech Headlines

No Headlines